TrimMedium
LMRI has broken a key multi‐week support cluster in a Stage 3 distribution, confirming medium-term bearish control despite an intact long-term uptrend. Price is flailing around the converged EMAs after the support failure, so immediate selling risks catching a short-covering bounce. We will trim into strength on a retest of the broken support and moving averages as preferred execution zones.
- ↑Q2 2026 adjusted EPS of $0.20 vs $0.16 expected; net income $2.7 M turnaround.
- ↑Record free cash flow in Q2 2026 supports growth initiatives or buybacks.
- ↓Profitability under pressure as operational costs constrain margins.
Full analysis →